Associated Papers
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2023
Coding Variants of the FMO3 Gene Are Associated with the Risk of Chronic Kidney Disease: A Case-Control Study.
Shorudi Dadi I et al.
Reports of Biochemistry & Molecular Biology, 2022
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.
Xu M et al.
The Journal of Pharmacology and Experimental Therapeutics, 2017
Pharmacogenetics of nicotine and associated smoking behaviors.
Tanner JA et al.
Current Topics in Behavioral Neurosciences, 2015
Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.
Shimizu M et al.
British Journal of Clinical Pharmacology, 2014
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
Söderberg MM et al.
The Pharmacogenomics Journal, 2013
Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population.
Shimizu M et al.
Molecular Genetics and Metabolism, 2012
Flavin-containing monooxygenase 3 gene polymorphisms in Turkish population.
Ozhan G et al.
Toxicology Mechanisms and Methods, 2012
Flavin-containing monooxygenases: mutations, disease and drug response.
Phillips IR et al.
Trends in Pharmacological Sciences, 2008
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3).
Allerston CK et al.
Pharmacogenetics and Genomics, 2007
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.
Koukouritaki SB et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Genetic polymorphisms of flavin-containing monooxygenase (FMO).
Krueger SK et al.
Drug Metabolism Reviews, 2002
Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.
Störmer E et al.
British Journal of Clinical Pharmacology, 2000
Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication.
Treacy EP et al.
Human Molecular Genetics, 1998
Allele and genotype frequencies of polymorphic FMO3 gene in two genetically distinct populations.
Hao D et al.
Cell Biochemistry and Function, 0